KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other financing activities (2016 - 2025)

Historic Other financing activities for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Q4 2025 value amounting to $1.1 million.

  • Vertex Pharmaceuticals' Other financing activities rose 2222.22% to $1.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 million, marking a year-over-year decrease of 4032.26%. This contributed to the annual value of $3.7 million for FY2025, which is 4032.26% down from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Other financing activities stood at $1.1 million, which was up 2222.22% from $1.1 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Other financing activities high stood at $3.5 million for Q1 2024, and its period low was -$1.5 million during Q4 2023.
  • For the 5-year period, Vertex Pharmaceuticals' Other financing activities averaged around $1.0 million, with its median value being $1.1 million (2022).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Other financing activities skyrocketed by 173908.05% in 2021, and later tumbled by 23636.36% in 2023.
  • Vertex Pharmaceuticals' Other financing activities (Quarter) stood at $1.4 million in 2021, then fell by 21.43% to $1.1 million in 2022, then plummeted by 236.36% to -$1.5 million in 2023, then skyrocketed by 160.0% to $900000.0 in 2024, then increased by 22.22% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q4 2025, $1.1 million for Q3 2025, and $700000.0 during Q2 2025.